MedTrace Logo

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

NCT06186934 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-04-29

No results posted yet for this study

Summary

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings

Conditions

  • Hyperphosphatemia

Interventions

DRUG

the standard-dose group (4 g/day)

Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia

Sponsors & Collaborators

  • Kyowa Kirin Korea Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-21
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06186934 on ClinicalTrials.gov